Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.

Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning VA, Warren RB, Exton LS, Mohd Mustapa MF.

Br J Dermatol. 2017 Sep;177(3):628-636. doi: 10.1111/bjd.15665. No abstract available.

PMID:
28513835
2.

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD; (Chair of Guideline Group).

Br J Dermatol. 2009 Nov;161(5):987-1019. doi: 10.1111/j.1365-2133.2009.09505.x. No abstract available.

PMID:
19857207
3.

A review of neurologic complications of biologic therapy in plaque psoriasis.

Lin EJ, Reddy S, Shah VV, Wu JJ.

Cutis. 2018 Jan;101(1):57-60. Review.

PMID:
29529105
4.

Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Iskandar IYK, Ashcroft DM, Warren RB, Evans I, McElhone K, Owen CM, Burden AD, Smith CH, Reynolds NJ, Griffiths CEM.

Br J Dermatol. 2017 May;176(5):1297-1307. doi: 10.1111/bjd.15027. Epub 2017 Mar 20.

PMID:
27589476
5.

Adverse reactions of biological therapy for psoriasis.

Brănişteanu DE, Voicu CM, Creţu A, Dimitriu A, Luca MC, Sălăvăstru CM.

Rev Med Chir Soc Med Nat Iasi. 2015 Jan-Mar;119(1):38-44.

PMID:
25970940
6.

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM, Reynolds NJ, Griffiths CEM.

J Invest Dermatol. 2015 Nov;135(11):2632-2640. doi: 10.1038/jid.2015.208. Epub 2015 Jun 8.

7.

ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.

Vilarrasa E, Notario J, Bordas X, López-Ferrer A, Gich IJ, Puig L.

J Am Acad Dermatol. 2016 Jun;74(6):1066-72. doi: 10.1016/j.jaad.2016.01.037. Epub 2016 Mar 19.

PMID:
27004803
8.

Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study.

Davison NJ, Warren RB, Mason KJ, McElhone K, Kirby B, Burden AD, Smith CH, Payne K, Griffiths CEM.

Br J Dermatol. 2017 Sep;177(3):828-836. doi: 10.1111/bjd.15551. Epub 2017 Jul 26.

PMID:
28386916
9.

Tuberculosis in the age of biologic therapy.

Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK.

J Am Acad Dermatol. 2008 Sep;59(3):363-80; quiz 382-4. doi: 10.1016/j.jaad.2008.05.033. Review.

PMID:
18694676
10.

To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.

Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW.

J Am Acad Dermatol. 2015 Sep;73(3):420-8.e1. doi: 10.1016/j.jaad.2015.06.004. Epub 2015 Jul 14. Review.

PMID:
26184440
11.

Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.

Kim WB, Marinas JE, Qiang J, Shahbaz A, Greaves S, Yeung J.

J Am Acad Dermatol. 2015 Aug;73(2):237-41. doi: 10.1016/j.jaad.2015.04.023. Epub 2015 May 28.

PMID:
26026334
12.

Biologic therapy in erythrodermic and pustular psoriasis.

Levin EC, Debbaneh M, Koo J, Liao W.

J Drugs Dermatol. 2014 Mar;13(3):342-54. Review.

PMID:
24595581
13.

Cardiovascular risk factors influence response to biological therapies in psoriasis.

Batalla A, González-Fernández D, González-Lara L, Abalde T, Salgado-Boquete L, Queiro-Silva R, Coto E, Coto-Segura P.

J Am Acad Dermatol. 2015 Aug;73(2):327-9. doi: 10.1016/j.jaad.2015.04.041. No abstract available.

PMID:
26183981
14.

Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.

Doshi JA, Takeshita J, Pinto L, Li P, Yu X, Rao P, Viswanathan HN, Gelfand JM.

J Am Acad Dermatol. 2016 Jun;74(6):1057-1065.e4. doi: 10.1016/j.jaad.2016.01.048. Epub 2016 Mar 4.

15.

Reduction in psoriasis related pruritus during biologic therapy.

Lazzeri L, Pescitelli L, Tripo L, Ricceri F, Prignano F.

Dermatol Ther. 2017 May;30(3). doi: 10.1111/dth.12442. Epub 2016 Nov 27. No abstract available.

PMID:
27891730
16.

Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.

Baniandrés O, Rodríguez-Soria VJ, Romero-Jiménez RM, Suárez R.

Actas Dermosifiliogr. 2015 Sep;106(7):569-77. doi: 10.1016/j.ad.2015.02.003. Epub 2015 Apr 30. English, Spanish.

PMID:
25935194
17.

Biologic therapy and screening for tuberculosis in a new service.

Peters J.

Br J Nurs. 2010 Nov 25-Dec 8;19(21):1351-4.

PMID:
21355360
18.

[Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis].

Ara M, Pérez A, Ferrando J.

Actas Dermosifiliogr. 2011 Nov;102(9):706-16. doi: 10.1016/j.ad.2011.03.014. Epub 2011 May 19. Spanish.

PMID:
21600532
19.

Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy.

Kauf TL, Yang JC, Kimball AB, Sundaram M, Bao Y, Okun M, Mulani P, Hauber AB, Johnson FR.

J Dermatolog Treat. 2015;26(6):507-13. doi: 10.3109/09546634.2015.1034071. Epub 2015 May 6.

PMID:
25946139
20.

Patient Adherence to Biologic Agents in Psoriasis.

Hsu DY, Gniadecki R.

Dermatology. 2016;232(3):326-33. doi: 10.1159/000444581. Epub 2016 Apr 20.

Supplemental Content

Support Center